Envoy Medical (COCH) makes contractor its new finance chief
Rhea-AI Filing Summary
Envoy Medical, Inc. (COCH) appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance, effective August 24, 2026. He will continue to serve as the company’s principal financial officer and principal accounting officer, transitioning from his prior contractor role as Interim Chief Financial Officer.
Under an Employment Agreement dated August 24, 2026, Mr. Potashnick will receive a base salary of $315,000 per year, an initial target annual bonus equal to 15% of base salary based on performance goals, and an initial equity award of 250,000 stock options with an exercise price of $0.746 per share, matching the Class A common stock closing price on his hire date. The agreement includes six months of severance compensation in certain termination scenarios. The company states he has no related-party transactions requiring disclosure and no family relationships with directors or executive officers.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Base salary: $315,000 per year
Target bonus percentage: 15% of base salary
Initial stock options: 250,000 stock options
+3 more
6 metrics
Base salary
$315,000 per year
Compensation for Chief Accounting Officer and Vice President of Finance under Employment Agreement dated August 24, 2026
Target bonus percentage
15% of base salary
Initial target bonus payable upon achievement of performance goals
Initial stock options
250,000 stock options
Equity award to Robert Potashnick as part of his compensation package
Stock option exercise price
$0.746 per share
Exercise price equals closing price of Class A Common Stock on August 24, 2026
Severance compensation period
Six months
Severance compensation in connection with certain terminations of employment
Age of executive
46
Age of Robert Potashnick at the time of appointment
Key Terms
principal financial officer, principal accounting officer, stock options, exercise price, +2 more
6 terms
principal financial officer financial
"will continue the duties as the Company’s principal financial officer"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
principal accounting officer financial
"and principal accounting officer"
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
stock options financial
"an initial equity award of 250,000 stock options at an exercise price"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"stock options at an exercise price of $0.746 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
severance compensation financial
"provides for six months of severance compensation in connection"
Emerging growth company regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What executive change did Envoy Medical, Inc. (COCH) announce on August 24, 2026?
Envoy Medical, Inc. appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance on August 24, 2026. He will also continue to serve as the company’s principal financial officer and principal accounting officer, formalizing his prior contractor role as Interim Chief Financial Officer.
What is the annual base salary for Envoy Medical’s new Chief Accounting Officer?
Under his Employment Agreement, Robert Potashnick will receive a base salary of $315,000 per year. This is part of his compensation package as Chief Accounting Officer and Vice President of Finance at Envoy Medical, Inc. (COCH).
What bonus opportunity does Envoy Medical (COCH) provide to Robert Potashnick?
Envoy Medical’s Employment Agreement grants Robert Potashnick an initial target bonus equal to 15% of his base salary, payable upon the company’s achievement of specified performance goals. This bonus is in addition to his base salary and equity award.
What equity award did Envoy Medical grant to Robert Potashnick?
Envoy Medical granted Robert Potashnick an initial equity award of 250,000 stock options with an exercise price of $0.746 per share, which is the closing price of the company’s Class A Common Stock on his August 24, 2026 hire date.
Does Envoy Medical’s agreement with Robert Potashnick include severance benefits?
Yes. The Employment Agreement provides for six months of severance compensation in connection with certain terminations of Robert Potashnick’s employment with Envoy Medical, Inc. (COCH).
AI-generated analysis. How Rhea-AI works. Not financial advice.
